Nkarta Inc 's Cash & cash equivalent grew by 93.74 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Nkarta Inc 's Quick Ratio to 1.72, Quick Ratio remained below Nkarta Inc average.

Within Major Pharmaceutical Preparations industry 348 other companies have achieved higher Quick Ratio than Nkarta Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 317 to 1810.

Explain Quick Ratio?
How much Cash & cash equivalents NKTX�s has?
What are NKTX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NKTX/financial-strength

https://api.csimarket.com/api/v1/companies/NKTX/fundamentals

https://api.csimarket.com/api/v1/companies/NKTX/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

NKTX Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	47.84 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-82.87 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	1.72	Subscribe	Subscribe	Subscribe	Subscribe
NKTX's Total Ranking	# 1810	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	12.63 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	93.74 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 349
Healthcare Sector	# 622
Overall Market	# 1810

Quick Ratio Statistics
High	Average	Low
35.66	16.27	0.36
(Dec 31 2020)		(Jun 30 2020)

Financial Statements
Nkarta Inc 's Current Liabilities	$ 28 Millions	Visit NKTX's Balance sheet
Nkarta Inc 's Cash & cash equivalent	$ 48 Millions	Visit NKTX's Balance sheet
Source of NKTX's Sales		Visit NKTX's Sales by Geography

Cumulative Nkarta Inc 's Quick Ratio

NKTX's Quick Ratio for the trailling 12 Months

NKTX Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	36.69 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-76.83 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	3.32	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3549	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	9.64 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-40.53 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to NKTX Financial Strength Comparisons >> Go to Compare NKTX Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q3 2026 to $28.07 millions, cumulative Quick Ratio decreased to 3.32 below the Nkarta Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 422 other companies have achieved higher Quick Ratio than Nkarta Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2519 to 3549.

Explain Quick Ratio?
How much Cash & cash equivalents NKTX�s has?
What are NKTX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 423
Healthcare Sector	# 860
Within the Market	# 3549

trailing twelve months Quick Ratio Statistics
High	Average	Low
32.2	16.05	6.95
(Jun 30 2021)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Spruce Biosciences Inc	4.69	$ 87.691 Millions	$ 18.710 Millions
Diamedica Therapeutics Inc	4.68	$ 34.905 Millions	$ 7.454 Millions
Eledon Pharmaceuticals Inc	4.61	$ 69.672 Millions	$ 15.099 Millions
Septerna Inc	4.56	$ 478.601 Millions	$ 104.863 Millions
Atossa Therapeutics Inc	4.37	$ 20.574 Millions	$ 4.709 Millions
Adial Pharmaceuticals Inc	4.35	$ 22.000 Millions	$ 5.056 Millions
Neurogene Inc	4.35	$ 78.942 Millions	$ 18.163 Millions
Entrada Therapeutics Inc	4.34	$ 112.302 Millions	$ 25.863 Millions
Gyre Therapeutics Inc	4.34	$ 86.190 Millions	$ 19.874 Millions
Serina Therapeutics Inc	4.28	$ 19.403 Millions	$ 4.529 Millions
Cellectar Biosciences Inc	4.24	$ 24.582 Millions	$ 5.798 Millions
Bio Green Med Solution Inc	4.24	$ 3.454 Millions	$ 0.815 Millions
Foghorn Therapeutics Inc	4.19	$ 156.222 Millions	$ 37.315 Millions
Calcimedica Inc	4.12	$ 13.768 Millions	$ 3.339 Millions
Revelation Biosciences Inc	3.92	$ 9.122 Millions	$ 2.328 Millions
Tonix Pharmaceuticals Holding Corp	3.87	$ 162.793 Millions	$ 42.026 Millions
Lyell Immunopharma Inc	3.83	$ 177.106 Millions	$ 46.271 Millions
Rapport Therapeutics Inc	3.68	$ 74.754 Millions	$ 20.302 Millions
Seaport Therapeutics Inc	3.60	$ 61.552 Millions	$ 17.106 Millions
Xilio Therapeutics Inc	3.47	$ 122.182 Millions	$ 35.258 Millions
Corbus Pharmaceuticals Holdings Inc	3.30	$ 115.337 Millions	$ 34.967 Millions
Maia Biotechnology Inc	3.30	$ 21.339 Millions	$ 6.474 Millions
Cytokinetics Incorporated	3.20	$ 1,130.021 Millions	$ 353.419 Millions
Elicio Therapeutics Inc	3.11	$ 30.900 Millions	$ 9.930 Millions
Talphera Inc	3.06	$ 14.157 Millions	$ 4.630 Millions
Harmony Biosciences Holdings inc	3.02	$ 771.138 Millions	$ 254.981 Millions
Phio Pharmaceuticals Corp	2.96	$ 10.609 Millions	$ 3.583 Millions
Zevra Therapeutics Inc	2.95	$ 122.148 Millions	$ 41.369 Millions
Nextcure Inc	2.95	$ 8.728 Millions	$ 2.960 Millions
Pyxis Oncology Inc	2.79	$ 55.572 Millions	$ 19.942 Millions

Date modified: 2026-11-06T05:45:35+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.